Re: Doctors are paid millions to dispense anemia drugs
- From: "Joe_Z" <Joe_Z@xxxxxxxxxxxxx>
- Date: Thu, 10 May 2007 00:52:33 GMT
It's all a freak'n FDA racket like we didn't already know it, now getting it
fixed would be some "new news" IMHO, thanks...Joe
yup, I'm going where this always leads and will till nov 08, nevermind but
thanks for reminding us just how currupt the system really is right now,
could it get much worse is the next question, eh, forget I said that and
thanks...
"Juba" <juba@xxxxxxxxxxxxxxxx> wrote in message
news:tpr9h.465.17.1@xxxxxxxxxxxxxxx
Key quotes:
"... documents given to The New York Times show that at just one practice
in the Pacific Northwest, a group of six cancer doctors received $2.7
million from Amgen for prescribing $9 million worth of the company's drugs
last year"
"The report, prepared by FDA staff scientists, said no evidence indicated
that the medicines either improved quality of life in patients or extended
their survival, while several studies suggested that the drugs can shorten
patients' lives when used at high doses."
"Combined with insurance reimbursements, the rebates enable many doctors
to profit substantially on the medicines they buy and then give to
patients."
"U.S. patients receive far more of the anemia drugs than patients
elsewhere, with dialysis patients in this country getting doses more than
twice as high as their counterparts in Europe."
------------------------------------
By Alex Berenson and Andrew Pollack
NEW YORK TIMES NEWS SERVICE
May 9, 2007
Two of the world's largest drug companies are paying hundreds of millions
of dollars to doctors every year in return for patients being given anemia
medicines, which regulators say may be unsafe at commonly used doses.
The payments are legal, but few people outside of the doctors who receive
them are aware of their size. Critics, including prominent cancer and
kidney doctors, say the payments give physicians an incentive to prescribe
the medicines at levels that might increase patients' risks of heart
attacks or strokes.
Industry analysts estimate that such payments - to cancer doctors and the
other big users of the drugs, kidney dialysis centers - total hundreds of
millions of dollars a year and are an important source of profit for
doctors and the centers. The payments have risen over the past several
years, as the makers of the drugs, Amgen and Johnson & Johnson, compete
for market share and try to expand the overall business.
Neither Amgen nor Johnson & Johnson has disclosed the total amount of the
payments. But documents given to The New York Times show that at just one
practice in the Pacific Northwest, a group of six cancer doctors received
$2.7 million from Amgen for prescribing $9 million worth of the company's
drugs last year.
Yesterday, the Food and Drug Administration added to concerns about the
drugs, releasing a report that suggested that their use might need to be
curtailed in cancer patients.
The report, prepared by FDA staff scientists, said no evidence indicated
that the medicines either improved quality of life in patients or extended
their survival, while several studies suggested that the drugs can shorten
patients' lives when used at high doses. Yesterday's report followed the
FDA's decision in March to strengthen warnings on the drugs' labels.
The report was released in advance of a hearing scheduled for tomorrow
during which an FDA advisory panel will consider whether the drugs are
overused.
The medicines - Aranesp and Epogen, from Amgen, and Procrit, from Johnson
& Johnson - are among the world's top-selling drugs, with combined sales
of $10 billion last year. In the United States, they represent the single
biggest drug expense for Medicare and are given to about a million
patients each year to treat anemia caused by kidney disease or cancer
chemotherapy.
Dr. Len Lichtenfeld, the deputy chief medical officer of the American
Cancer Society, said patients and doctors would benefit from fuller
disclosure about the payments and the profits that doctors can make from
them. "I suspect that Medicare is going to take a very careful look at
what is going on here," he said.
Still, the anemia drugs can help patients' quality of life when used
appropriately, Lichtenfeld said.
Most doctors and patients say the drugs are very helpful when used to
correct severe anemia. But there is little evidence that the drugs make
much difference for patients with moderate anemia.
Federal laws bar drug companies from paying doctors to prescribe medicines
given in pill form and purchased by patients from pharmacies.
But companies can rebate part of the price that doctors pay for drugs,
like the anemia medicines, which they dispense in their offices as part of
treatment. The anemia drugs are injected or given intravenously, in
physicians' offices or dialysis centers.
Doctors receive the rebates after they buy the drugs from the companies.
But they also receive reimbursement from Medicare or private insurers for
the drugs, often at a mark-up over the doctor's purchase price.
Combined with insurance reimbursements, the rebates enable many doctors to
profit substantially on the medicines they buy and then give to patients.
Johnson & Johnson said yesterday in a statement that its rebates were not
intended to induce doctors to prescribe more medicine. Instead, the
rebates "reflect intense competition" in the market for the drugs, the
company said.
Amgen said that rebates are normal commercial practice and that it had
always properly promoted its drugs.
Both companies' stocks fell yesterday after release of the FDA report.
Since 1991, when the first of the drugs was still relatively new, the
average dose given to dialysis patients in this country has nearly
tripled. About 50 percent of dialysis patients receive enough of the drugs
to raise their red blood cell counts above the level considered risky by
the FDA.
U.S. patients receive far more of the anemia drugs than patients
elsewhere, with dialysis patients in this country getting doses more than
twice as high as their counterparts in Europe.
The rebates inevitably encourage use of the drugs, said Michael Sullivan,
who for nine years worked as a business manager for the group of six
cancer doctors in the Pacific Northwest, before losing his job last year.
Sullivan provided the Times with documentation that shows the size of the
rebates, on the condition that the group not be identified. "Personally, I
think rebates should go away," said Sullivan, whose late father was a
kidney dialysis patient who died of a heart attack while taking epoetin.
The anemia medicines are known generically as epoetin and darbepoetin, and
often referred to simply as EPO.
--
Juba
www.masterjuba.com
.
- References:
- Prev by Date: Re: RIGHT NUT PAIN
- Next by Date: Re: sunburnt-like pain
- Previous by thread: Doctors are paid millions to dispense anemia drugs
- Next by thread: RIGHT NUT PAIN
- Index(es):
Relevant Pages
|
